Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Basal Ganglia Diseases » Parkinsonian Disorders
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Movement Disorders » Parkinsonian Disorders
Description
A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. MeSH
Hierarchy View
Subtype Terms (3)
Lewy Body Disease
36 drugs (19 approved, 17 experimental)
Parkinson Disease
457 drugs (169 approved, 288 experimental)
Parkinson Disease, Secondary
6 approved drugs
Approved Indicated Drugs (2)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (6)
Phase 1 Indicated Drugs (3)
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
